Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Lowered by Wall Street Zen

Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

A number of other analysts have also commented on SGMO. Barclays reaffirmed an “equal weight” rating and set a $1.00 target price (down previously from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Sangamo Therapeutics currently has an average rating of “Hold” and an average price target of $4.33.

Sangamo Therapeutics Trading Up 4.4%

Shares of NASDAQ:SGMO opened at $0.54 on Friday. Sangamo Therapeutics has a 1-year low of $0.36 and a 1-year high of $1.40. The stock has a market capitalization of $180.19 million, a P/E ratio of -1.22 and a beta of 1.29. The business has a 50-day moving average price of $0.44 and a two-hundred day moving average price of $0.52.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.08). The business had revenue of $0.58 million for the quarter, compared to analyst estimates of $34.40 million. Sangamo Therapeutics had a negative return on equity of 813.95% and a negative net margin of 331.28%. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Sangamo Therapeutics by 23.9% in the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock valued at $7,817,000 after buying an additional 2,240,422 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Sangamo Therapeutics by 182.7% during the third quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock worth $1,669,000 after acquiring an additional 1,602,107 shares in the last quarter. GSA Capital Partners LLP grew its stake in Sangamo Therapeutics by 63.1% in the third quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after acquiring an additional 1,417,029 shares during the period. Wasatch Advisors LP grew its stake in Sangamo Therapeutics by 17.7% in the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after acquiring an additional 1,215,653 shares during the period. Finally, Oracle Investment Management Inc. bought a new stake in shares of Sangamo Therapeutics in the third quarter worth about $677,000. Institutional investors and hedge funds own 56.92% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.